文献速递泌尿生殖与妇科肿瘤放疗

19 Gy单次高剂量率近距离放疗治疗低中危前列腺癌的初步结果

Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-09

这项前瞻性研究评估了63例低中危前列腺癌患者接受19 Gy单次高剂量率近距离放疗的毒性和初步疗效。中位随访2.9年,58例可分析患者中3年累积生化失败率为6.8%,急性和慢性2级泌尿生殖毒性分别为12.1%和10.3%,无3级泌尿毒性。结论认为该方案耐受性良好,初步生化和临床疾病控制率令人满意。

要点

  • 19 Gy单次HDR近距离放疗在低中危前列腺癌中急性2级泌尿生殖毒性为12.1%。
  • 慢性2级泌尿生殖毒性为10.3%,未发生3级泌尿毒性。
  • 3年累积生化失败率为6.8%,初步疾病控制良好。

核心结论

  • 单次19 Gy高剂量率近距离放疗耐受性良好,初步生化和临床疾病控制率良好。

研究设计与样本

  • 这项前瞻性研究经机构审查委员会批准,共纳入63例低中危前列腺癌患者,58例有可分析数据。
  • eligible患者肿瘤分期≤T2a、前列腺特异性抗原≤15 ng/mL、Gleason评分≤7。
  • 腺体体积>50 cm3或基线美国泌尿协会症状评分>12的患者被排除。

主要发现

  • 中位随访2.9年(范围0.3-5.2年),中位年龄61.4岁,治疗时中位腺体体积34.8 cm3。
  • 58例中91%为T1期,71% Gleason评分≤6(29%为7分),治疗前中位PSA为5.1 ng/mL。
  • 急性和慢性2级泌尿生殖毒性发生率分别为12.1%和10.3%,无3级泌尿毒性。
  • 无患者发生急性≥2级直肠毒性,2例发生≥2级慢性胃肠道毒性。
  • 3例出现生化失败,3年累积发生率估计为6.8%。

关键数值与推荐

  • 处方剂量为19 Gy,使用192Ir,处方到前列腺,未加额外外扩边界。

临床怎么用

  • 对于低中危前列腺癌患者,可考虑19 Gy单次HDR近距离放疗作为治疗选择,需注意泌尿生殖和胃肠道毒性。

局限性

  • 随访时间较短,中位仅2.9年,且5例患者退出导致数据不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the toxicity and preliminary clinical outcomes of a prospective trial evaluating 19-Gy, single-fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 63 patients were treated according to an institutional review board-approved prospective study of single-fraction HDR brachytherapy. Eligible patients had tumor stage ≤T2a, prostate-specific antigen level ≤15 ng/mL, and Gleason score ≤7. Patients with a prostate gland volume >50 cm3 and baseline American Urologic Association symptom score >12 were ineligible. Patients underwent transrectal ultrasound-guided transperineal implantation of the prostate, followed by single-fraction HDR brachytherapy. Treatment was delivered using 192Ir to a dose of 19 Gy prescribed to the prostate, with no additional margin applied. RESULTS: Of the 63 patients, 58 had data available for analysis. Five patients had withdrawn consent during the follow-up period. The median follow-up period was 2.9 years (range 0.3-5.2). The median age was 61.4 years. The median gland volume at treatment was 34.8 cm3. Of the 58 patients, 91% had T1 disease, 71% had Gleason score ≤6 (29% with Gleason score 7), and the median pretreatment prostate-specific antigen level was 5.1 ng/mL. The acute and chronic grade 2 genitourinary toxicity incidence was 12.1% and 10.3%, respectively. No grade 3 urinary toxicity occurred. No patients experienced acute rectal toxicity grade ≥2, and 2 experienced grade ≥2 chronic gastrointestinal toxicity. Three patients experienced biochemical failure, yielding a 3-year cumulative incidence estimate of 6.8%. CONCLUSIONS: Single-fraction HDR brachytherapy is well-tolerated, with favorable preliminary biochemical and clinical disease control rates.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Krauss DJ, Ye H, Martinez AA, et al. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy. Int J Radiat Oncol Biol Phys. 2016. PMID: 27979460. doi:10.1016/j.ijrobp.2016.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。